ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Boehringer Ingelheim, Mannkind and Maruho side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Boehringer Ingelheim×Mannkind×Maruho×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Boehringer IngelheimMannkindMaruho
studies on the registry2,3056639
open to participants now6130
phase 3 studies under way2800
reach primary completion within a year4510
programswith a study of their own in two years45+21 named only4none read

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseBoehringer IngelheimMannkindMaruho
Phase 1

Boehringer Ingelheim: 18 of its 45 programs at phase 1

  1. BI 3821001phase 1
  2. BI 3000202_low dosephase 1
  3. BI 3776528phase 1
  4. BI 3810944phase 1
  5. BI 3814916phase 1

and 13 more — sign in to see them all

40%

Mannkind: 1 of its 4 programs at phase 1

  1. nintedanibphase 1
25%
–
Phase 2

Boehringer Ingelheim: 15 of its 45 programs at phase 2

  1. BI 3034701phase 2
  2. Anti-SIRPa Monoclonal Antibody BI 770371phase 2
  3. BI 1584862phase 2
  4. BI 1815368phase 2
  5. BI 3000202phase 2

and 10 more — sign in to see them all

33%

Mannkind: 2 of its 4 programs at phase 2

  1. Basal insulinphase 2
  2. Nintedanib Dry Powder Inhalationphase 2
50%
–
Phase 3

Boehringer Ingelheim: 9 of its 45 programs at phase 3

  1. obrixtamigphase 3
  2. survodutidephase 3
  3. nerandomilastphase 3
  4. verducatibphase 3
  5. zongertinibphase 3

and 4 more — sign in to see them all

20%
00%–
Approved, new studies

Boehringer Ingelheim: 3 of its 45 programs at approved, new studies

  1. empagliflozinapproved, new study
  2. Tenecteplaseapproved, new study
  3. Pramipexoleapproved, new study
7%

Mannkind: 1 of its 4 programs at approved, new studies

  1. Insulin, Regular, Humanapproved, new study
25%
–

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Boehringer Ingelheim20 readouts · 3 phase 3·

Boehringer Ingelheim, Dec ’26: 8 programs whose next study reaches primary completion, 1 in phase 3

  1. survodutidephase 3 · Dec 8 · NCT07768813
  2. zongertinibphase 3 · Dec 10 · NCT06151574
  3. empagliflozinapproved, new study · Dec 11 · NCT07845630
  4. vicadrostatphase 3 · Dec 11 · NCT07845630
  5. verducatibphase 3 · Dec 14 · NCT07781631

and 3 more — sign in to see them all

·

Boehringer Ingelheim, Feb ’27: 1 program whose next study reaches primary completion

  1. BI 3776528phase 1 · Feb 3 · NCT06745297

Boehringer Ingelheim, Mar ’27: 4 programs whose next study reaches primary completion

  1. BI 764524phase 2 · Mar 5 · NCT06321302
  2. ezabenlimabphase 3 · Mar 8 · NCT05846516
  3. BI 765423phase 2 · Mar 11 · NCT07036523
  4. BI 3812465phase 2 · Mar 23 · NCT07553429

Boehringer Ingelheim, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. nerandomilastphase 3 · Apr 15 · NCT06806592
·

Boehringer Ingelheim, Jun ’27: 1 program whose next study reaches primary completion

  1. BI 3821001phase 1 · Jun 22 · NCT07908004

Boehringer Ingelheim, Jul ’27: 2 programs whose next study reaches primary completion

  1. BI 3814916phase 1 · Jul 12 · NCT07486115
  2. BI 3032950phase 2 · Jul 30 · NCT06636656

Boehringer Ingelheim, Aug ’27: 2 programs whose next study reaches primary completion

  1. BI 3802876phase 2 · Aug 5 · NCT07325526
  2. Anti-SIRPa Monoclonal Antibody BI 770371phase 2 · Aug 31 · NCT06806852
·

Boehringer Ingelheim, Oct ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. Tenecteplaseapproved, new study · Oct 2 · NCT07361302
Mannkind2 readouts · 0 phase 3····

Mannkind, Mar ’27: 2 programs whose next study reaches primary completion

  1. Basal insulinphase 2 · Mar 0 · NCT07224321
  2. Insulin, Regular, Humanapproved, new study · Mar 0 · NCT07224321
·······
Maruho0 readouts · 0 phase 3············
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Boehringer Ingelheim

New programs 3

  • BI 4015092phase 1 · first study · Nov 3
  • BI 3968621phase 1 · first study · Sep 25
  • pumitamigphase 2 · first study · Sep 22 · Carcinoma, Non-Small-Cell Lung

Reached a new phase 1

  • BI 3810477phase 2 · Nov 3 · Idiopathic Pulmonary Fibrosis

Study stopped 0

None

Primary completion later 7

Mannkind

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Maruho

No programs read for this company.

Where they overlap

Conditions where at least two of them have programs: 6 in all. A program counts in each condition its studies name most.

ConditionBoehringer IngelheimMannkindMaruho
Idiopathic Pulmonary Fibrosis2 of 3 · compare here

Boehringer Ingelheim in Idiopathic Pulmonary Fibrosis: 4 programs

  1. nerandomilastphase 3
  2. BI 3810477phase 2
  3. BI 765423phase 2
  4. BI 1819479phase 2

Their studies: Boehringer Ingelheim’s studies of Idiopathic Pulmonary Fibrosis in search

Mannkind in Idiopathic Pulmonary Fibrosis: 2 programs

  1. Nintedanib Dry Powder Inhalationphase 2
  2. nintedanibphase 1

Their studies: Mannkind’s studies of Idiopathic Pulmonary Fibrosis in search

–
Carcinoma, Non-Small-Cell Lung2 of 3 · compare here

Boehringer Ingelheim in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. zongertinibphase 3
  2. ezabenlimabphase 3
  3. Etoposidephase 3
  4. pumitamigphase 2

Their studies: Boehringer Ingelheim’s studies of Carcinoma, Non-Small-Cell Lung in search

Mannkind in Carcinoma, Non-Small-Cell Lung: 1 program

  1. nintedanibphase 1

Their studies: Mannkind’s studies of Carcinoma, Non-Small-Cell Lung in search

–
Diabetes Mellitus, Type 22 of 3 · compare here

Boehringer Ingelheim in Diabetes Mellitus, Type 2: 3 programs

  1. survodutidephase 3
  2. vicadrostatphase 3
  3. empagliflozinapproved, new study

Their studies: Boehringer Ingelheim’s studies of Diabetes Mellitus, Type 2 in search

Mannkind in Diabetes Mellitus, Type 2: 1 program

  1. Insulin, Regular, Humanapproved, new study

Their studies: Mannkind’s studies of Diabetes Mellitus, Type 2 in search

–
Diabetes Mellitus, Type 12 of 3 · compare here

Boehringer Ingelheim in Diabetes Mellitus, Type 1: 1 program

  1. empagliflozinapproved, new study

Their studies: Boehringer Ingelheim’s studies of Diabetes Mellitus, Type 1 in search

Mannkind in Diabetes Mellitus, Type 1: 2 programs

  1. Basal insulinphase 2
  2. Insulin, Regular, Humanapproved, new study

Their studies: Mannkind’s studies of Diabetes Mellitus, Type 1 in search

–
Lung Diseases, Interstitial2 of 3 · compare here

Boehringer Ingelheim in Lung Diseases, Interstitial: 1 program

  1. nerandomilastphase 3

Their studies: Boehringer Ingelheim’s studies of Lung Diseases, Interstitial in search

Mannkind in Lung Diseases, Interstitial: 1 program

  1. nintedanibphase 1

Their studies: Mannkind’s studies of Lung Diseases, Interstitial in search

–
Neoplasms2 of 3 · compare here

Boehringer Ingelheim in Neoplasms: 1 program

  1. ezabenlimabphase 3

Their studies: Boehringer Ingelheim’s studies of Neoplasms in search

Mannkind in Neoplasms: 1 program

  1. nintedanibphase 1

Their studies: Mannkind’s studies of Neoplasms in search

–

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Boehringer Ingelheim 24 of 45 · Mannkind 1 of 4 · Maruho 0 of 0 programs (10 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Boehringer Ingelheim: 21).